labscreen single antigen hla class class ii assays (Thermo Fisher)
Thermo Fisher is a verified supplier 
Thermo Fisher manufactures this product 
90
Structured Review
Thermo Fisher
labscreen single antigen hla class class ii assays
Labscreen Single Antigen Hla Class Class Ii Assays, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/labscreen+single+antigen+hla+class+class+ii/pm39873804-36-14-17
Average 90 stars, based on 1 article reviews
Labscreen Single Antigen Hla Class Class Ii Assays, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/labscreen+single+antigen+hla+class+class+ii/pm39873804-36-14-17
Average 90 stars, based on 1 article reviews
labscreen single antigen hla class class ii assays - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Transplantation Assay:Article Title: Which is the best predictor of de novo donor-specific antibodies in a cohort of non-sensitized first kidney transplantation: Antigenic, allelic, epitope, or physiochemical HLA mismatches? Article Snippet: This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record.. Please cite this article as doi: 10.1111/ctr.13508 This article is protected by copyright.. All rights reserved. Article Title: Safety and Efficacy of DT-DEC01 Therapy in Duchenne Muscular Dystrophy Patients: A 12 - Month Follow-Up Study After Systemic Intraosseous Administration Article Snippet: In the case of a positive result, further analysis was employed to determine the presence of the pre-existing DSA (LABScreen Single Antigen HLA Class I and Class II, One Lambda, Luminex platform). Article Title: Dystrophin Expressing Chimeric (DEC) Cell Therapy for Duchenne Muscular Dystrophy: A First-in-Human Study with Minimum 6 Months Follow-up. Article Snippet: In the case of a positive result, further analysis was employed to determine the presence of the pre-existing DSA (LABScreen Single Antigen HLA Class I and Class II, One Lambda, Luminex platform). Article Title: Clinical Significance of De Novo Donor Specific Antibody Based on the Type of Kidney Transplantation. Article Snippet: Transplantat ABSTRACT Background.. Preemptive living donor kidney transplantation (P-LDKT) has shown a better prognosis than nonpreemptive living donor KT (NP-LDKT) or deceased donor KT (DDKT).. However, association between KT type and de novo donor specific antibody (dnDSA) is uncertain. Article Title: Dynamics of B cell recovery following kidney/bone marrow transplant recipients Article Snippet: Serum samples showing positive reactivity to HLA Class I or HLA Class II were further tested using beads coated with single Article Title: Dystrophin Expressing Chimeric (DEC) Cell Therapy for Duchenne Muscular Dystrophy: A First-in-Human Study with Minimum 6 Months Follow-up Article Snippet: In the case of a positive result, further analysis was employed to determine the presence of the pre-existing DSA (LABScreen Single Antigen HLA Class I and Class II, One Lambda, Luminex platform). Antigen Assay:Article Title: Which is the best predictor of de novo donor-specific antibodies in a cohort of non-sensitized first kidney transplantation: Antigenic, allelic, epitope, or physiochemical HLA mismatches? Article Snippet: This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record.. Please cite this article as doi: 10.1111/ctr.13508 This article is protected by copyright.. All rights reserved. Article Title: Safety and Efficacy of DT-DEC01 Therapy in Duchenne Muscular Dystrophy Patients: A 12 - Month Follow-Up Study After Systemic Intraosseous Administration Article Snippet: In the case of a positive result, further analysis was employed to determine the presence of the pre-existing DSA (LABScreen Single Antigen HLA Class I and Class II, One Lambda, Luminex platform). Article Title: Dystrophin Expressing Chimeric (DEC) Cell Therapy for Duchenne Muscular Dystrophy: A First-in-Human Study with Minimum 6 Months Follow-up. Article Snippet: In the case of a positive result, further analysis was employed to determine the presence of the pre-existing DSA (LABScreen Single Antigen HLA Class I and Class II, One Lambda, Luminex platform). Article Title: Clinical Significance of De Novo Donor Specific Antibody Based on the Type of Kidney Transplantation. Article Snippet: Transplantat ABSTRACT Background.. Preemptive living donor kidney transplantation (P-LDKT) has shown a better prognosis than nonpreemptive living donor KT (NP-LDKT) or deceased donor KT (DDKT).. However, association between KT type and de novo donor specific antibody (dnDSA) is uncertain. Article Title: Dynamics of B cell recovery following kidney/bone marrow transplant recipients Article Snippet: Serum samples showing positive reactivity to HLA Class I or HLA Class II were further tested using beads coated with single Article Title: Dystrophin Expressing Chimeric (DEC) Cell Therapy for Duchenne Muscular Dystrophy: A First-in-Human Study with Minimum 6 Months Follow-up Article Snippet: In the case of a positive result, further analysis was employed to determine the presence of the pre-existing DSA (LABScreen Single Antigen HLA Class I and Class II, One Lambda, Luminex platform). Fluorescence:Article Title: Which is the best predictor of de novo donor-specific antibodies in a cohort of non-sensitized first kidney transplantation: Antigenic, allelic, epitope, or physiochemical HLA mismatches? Article Snippet: This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record.. Please cite this article as doi: 10.1111/ctr.13508 This article is protected by copyright.. All rights reserved. Article Title: Safety and Efficacy of DT-DEC01 Therapy in Duchenne Muscular Dystrophy Patients: A 12 - Month Follow-Up Study After Systemic Intraosseous Administration Article Snippet: In the case of a positive result, further analysis was employed to determine the presence of the pre-existing DSA (LABScreen Single Antigen HLA Class I and Class II, One Lambda, Luminex platform). Article Title: Dystrophin Expressing Chimeric (DEC) Cell Therapy for Duchenne Muscular Dystrophy: A First-in-Human Study with Minimum 6 Months Follow-up. Article Snippet: In the case of a positive result, further analysis was employed to determine the presence of the pre-existing DSA (LABScreen Single Antigen HLA Class I and Class II, One Lambda, Luminex platform). Article Title: Clinical Significance of De Novo Donor Specific Antibody Based on the Type of Kidney Transplantation. Article Snippet: Transplantat ABSTRACT Background.. Preemptive living donor kidney transplantation (P-LDKT) has shown a better prognosis than nonpreemptive living donor KT (NP-LDKT) or deceased donor KT (DDKT).. However, association between KT type and de novo donor specific antibody (dnDSA) is uncertain. Article Title: Dynamics of B cell recovery following kidney/bone marrow transplant recipients Article Snippet: Serum samples showing positive reactivity to HLA Class I or HLA Class II were further tested using beads coated with single Article Title: Dystrophin Expressing Chimeric (DEC) Cell Therapy for Duchenne Muscular Dystrophy: A First-in-Human Study with Minimum 6 Months Follow-up Article Snippet: In the case of a positive result, further analysis was employed to determine the presence of the pre-existing DSA (LABScreen Single Antigen HLA Class I and Class II, One Lambda, Luminex platform). Luminex:Article Title: Which is the best predictor of de novo donor-specific antibodies in a cohort of non-sensitized first kidney transplantation: Antigenic, allelic, epitope, or physiochemical HLA mismatches? Article Snippet: This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record.. Please cite this article as doi: 10.1111/ctr.13508 This article is protected by copyright.. All rights reserved. Article Title: Safety and Efficacy of DT-DEC01 Therapy in Duchenne Muscular Dystrophy Patients: A 12 - Month Follow-Up Study After Systemic Intraosseous Administration Article Snippet: In the case of a positive result, further analysis was employed to determine the presence of the pre-existing DSA (LABScreen Single Antigen HLA Class I and Class II, One Lambda, Luminex platform). Article Title: Dystrophin Expressing Chimeric (DEC) Cell Therapy for Duchenne Muscular Dystrophy: A First-in-Human Study with Minimum 6 Months Follow-up. Article Snippet: In the case of a positive result, further analysis was employed to determine the presence of the pre-existing DSA (LABScreen Single Antigen HLA Class I and Class II, One Lambda, Luminex platform). Article Title: Clinical Significance of De Novo Donor Specific Antibody Based on the Type of Kidney Transplantation. Article Snippet: Transplantat ABSTRACT Background.. Preemptive living donor kidney transplantation (P-LDKT) has shown a better prognosis than nonpreemptive living donor KT (NP-LDKT) or deceased donor KT (DDKT).. However, association between KT type and de novo donor specific antibody (dnDSA) is uncertain. Article Title: Dynamics of B cell recovery following kidney/bone marrow transplant recipients Article Snippet: Serum samples showing positive reactivity to HLA Class I or HLA Class II were further tested using beads coated with single Article Title: Dystrophin Expressing Chimeric (DEC) Cell Therapy for Duchenne Muscular Dystrophy: A First-in-Human Study with Minimum 6 Months Follow-up Article Snippet: In the case of a positive result, further analysis was employed to determine the presence of the pre-existing DSA (LABScreen Single Antigen HLA Class I and Class II, One Lambda, Luminex platform). Labeling:Article Title: Which is the best predictor of de novo donor-specific antibodies in a cohort of non-sensitized first kidney transplantation: Antigenic, allelic, epitope, or physiochemical HLA mismatches? Article Snippet: This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record.. Please cite this article as doi: 10.1111/ctr.13508 This article is protected by copyright.. All rights reserved. Article Title: Safety and Efficacy of DT-DEC01 Therapy in Duchenne Muscular Dystrophy Patients: A 12 - Month Follow-Up Study After Systemic Intraosseous Administration Article Snippet: In the case of a positive result, further analysis was employed to determine the presence of the pre-existing DSA (LABScreen Single Antigen HLA Class I and Class II, One Lambda, Luminex platform). Article Title: Dystrophin Expressing Chimeric (DEC) Cell Therapy for Duchenne Muscular Dystrophy: A First-in-Human Study with Minimum 6 Months Follow-up. Article Snippet: In the case of a positive result, further analysis was employed to determine the presence of the pre-existing DSA (LABScreen Single Antigen HLA Class I and Class II, One Lambda, Luminex platform). Article Title: Clinical Significance of De Novo Donor Specific Antibody Based on the Type of Kidney Transplantation. Article Snippet: Transplantat ABSTRACT Background.. Preemptive living donor kidney transplantation (P-LDKT) has shown a better prognosis than nonpreemptive living donor KT (NP-LDKT) or deceased donor KT (DDKT).. However, association between KT type and de novo donor specific antibody (dnDSA) is uncertain. Article Title: Dynamics of B cell recovery following kidney/bone marrow transplant recipients Article Snippet: Serum samples showing positive reactivity to HLA Class I or HLA Class II were further tested using beads coated with single Article Title: Dystrophin Expressing Chimeric (DEC) Cell Therapy for Duchenne Muscular Dystrophy: A First-in-Human Study with Minimum 6 Months Follow-up Article Snippet: In the case of a positive result, further analysis was employed to determine the presence of the pre-existing DSA (LABScreen Single Antigen HLA Class I and Class II, One Lambda, Luminex platform). |